Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IRX 2

Next Previous
Drug Profile

IRX 2

Alternative Names: Citoplurikin; IRX-2

Latest Information Update: 22 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator IRX Therapeutics
  • Developer City of Hope National Medical Center; Ernexa Therapeutics; H. Lee Moffitt Cancer Center and Research Institute; National Cancer Institute (USA); Providence Health & Services; University of Southern California
  • Class Antineoplastics; Cytokines
  • Mechanism of Action Dendritic cell stimulants; Natural killer cell stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Squamous cell cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cervical intraepithelial neoplasia; Squamous cell cancer; Triple negative breast cancer; Vulvar intraepithelial neoplasia
  • No development reported Liver cancer; Solid tumours

Most Recent Events

  • 25 Sep 2025 Phase-I development is ongoing USA (NCT02950259)
  • 25 Sep 2025 Providence Health & Services and Brooklyn ImmunoTherapeutics completes a phase I trial in Triple-negative-breast cancer (In children, In adults, In the elderly, Early-stage disease, Neoadjuvant therapy) in USA (SC) (NCT02950259)
  • 28 Jun 2025 No recent reports of development identified for phase-I development in Squamous-cell-cancer(Combination therapy, Metastatic disease, Recurrent, Second-line therapy or greater) in USA (Parenteral, Injection)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top